Voyager Therapeutics director granted 30,000 options

Voyager Therapeutics, Inc. reported that director Steven Hyman received a grant of stock options to buy 30,000 shares of common stock at an exercise price of $3.43 per share.

Rhea-AI Filing Summary

Voyager Therapeutics, Inc. reported that director Steven Hyman received a grant of stock options to buy 30,000 shares of common stock at an exercise price of $3.43 per share. The award was made under the company’s 2025 Stock Incentive Plan as part of its director compensation policy.

All 30,000 underlying shares vest upon the earlier of one year from the grant date or the next annual meeting of stockholders, provided he continues to serve as a director. The filing does not show any option exercises or open-market share purchases or sales associated with this grant.

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider Hyman Steven

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct)

Footnotes (1)

1. F1. This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

Key Figures

Option grant size: 30,000 shares Exercise price: $3.43 per share Underlying common stock: 30,000 shares +1 more

4 metrics

Option grant size 30,000 shares Stock Option (Right to Buy) granted to director on 2026-06-09

Exercise price $3.43 per share Conversion or exercise price of the granted stock option

Underlying common stock 30,000 shares Common Stock underlying the stock option award

Option expiration 2036-06-09 Expiration date of the stock option grant

Key Terms

Stock Option (Right to Buy), 2025 Stock Incentive Plan, director compensation policy, vesting commencement date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

2025 Stock Incentive Plan financial

"This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc."

director compensation policy financial

"in accordance with its director compensation policy."

vesting commencement date financial

"The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

annual meeting of stockholders financial

"underlying the option vest upon the earlier of the one-year anniversary ... or the date of the next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Voyager Therapeutics (VYGR) disclose in this Form 4 for Steven Hyman?

Voyager Therapeutics reported that director Steven Hyman received a grant of stock options for 30,000 shares at a $3.43 exercise price. The grant was issued under the 2025 Stock Incentive Plan as part of the company’s standard director compensation program.

How many Voyager Therapeutics (VYGR) options were granted to Steven Hyman and at what price?

Steven Hyman was granted stock options covering 30,000 shares of Voyager Therapeutics common stock with a $3.43 per share exercise price. These options provide the right to buy shares in the future rather than reflecting an open-market purchase today.

When do Steven Hyman’s Voyager Therapeutics (VYGR) stock options vest?

All 30,000 Voyager Therapeutics stock options vest on the earlier of one year from the grant date or the next annual meeting of stockholders. Vesting is contingent on Hyman’s continued service as a director through that vesting date, per the footnote disclosure.

Is the Voyager Therapeutics (VYGR) Form 4 for Steven Hyman a stock sale or purchase?

The Form 4 reports a compensation-related option grant, not an open-market stock sale or purchase. It records an award of options to acquire 30,000 shares at $3.43, with no corresponding exercises or trades in Voyager Therapeutics common stock reported in this filing.

Under what plan were Steven Hyman’s Voyager Therapeutics (VYGR) options granted?

The options were issued under Voyager Therapeutics’ 2025 Stock Incentive Plan in line with its director compensation policy. This indicates the award is part of the company’s structured equity compensation program for board members rather than a discretionary market transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 04:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hyman Steven

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, INC.

75 HAYDEN AVENUE

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [ VYGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.43	06/09/2026		A		30,000		(1)	06/09/2036	Common Stock	30,000	$0	$30,000	D

Explanation of Responses:

1. This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

Remarks:

Exhibit 24: Power of Attorney

	/s/ Gregory L. Shiferman, as Attorney-in-Fact for Steven Hyman	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)